Wall Street Zen upgraded shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a hold rating to a buy rating in a report released on Saturday.
BMRN has been the subject of several other research reports. Morgan Stanley boosted their price objective on BioMarin Pharmaceutical from $119.00 to $124.00 and gave the stock an “overweight” rating in a research report on Friday. Oppenheimer raised their target price on BioMarin Pharmaceutical from $95.00 to $97.00 and gave the company an “outperform” rating in a report on Friday. Royal Bank Of Canada dropped their price target on BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating on the stock in a research report on Tuesday, July 7th. Sanford C. Bernstein dropped their price target on BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 5th. Finally, HC Wainwright upped their price target on BioMarin Pharmaceutical from $50.00 to $60.00 and gave the stock a “neutral” rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $88.00.
BioMarin Pharmaceutical Stock Performance
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last released its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The firm had revenue of $989.71 million during the quarter, compared to analyst estimates of $932.03 million. During the same quarter in the previous year, the business earned $1.44 EPS. The business’s revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, sell-side analysts anticipate that BioMarin Pharmaceutical will post 4.22 EPS for the current year.
Institutional Investors Weigh In On BioMarin Pharmaceutical
Institutional investors have recently added to or reduced their stakes in the company. Paragon Capital Management Inc. bought a new position in shares of BioMarin Pharmaceutical in the fourth quarter valued at about $1,191,000. Swedbank AB grew its holdings in BioMarin Pharmaceutical by 70.6% during the 4th quarter. Swedbank AB now owns 796,737 shares of the biotechnology company’s stock worth $47,350,000 after acquiring an additional 329,794 shares during the last quarter. LSV Asset Management grew its holdings in BioMarin Pharmaceutical by 4.3% during the 4th quarter. LSV Asset Management now owns 882,200 shares of the biotechnology company’s stock worth $52,429,000 after acquiring an additional 36,700 shares during the last quarter. C WorldWide Group Holding A S increased its position in BioMarin Pharmaceutical by 12.6% in the 4th quarter. C WorldWide Group Holding A S now owns 267,851 shares of the biotechnology company’s stock valued at $15,918,000 after acquiring an additional 30,000 shares in the last quarter. Finally, KBC Group NV increased its position in BioMarin Pharmaceutical by 10.0% in the 4th quarter. KBC Group NV now owns 168,779 shares of the biotechnology company’s stock valued at $10,031,000 after acquiring an additional 15,362 shares in the last quarter. 98.71% of the stock is owned by institutional investors and hedge funds.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.
The company’s commercial portfolio includes several approved therapies targeting inherited disorders.
Read More
- Five stocks we like better than BioMarin Pharmaceutical
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
